Navigation Links
Biotech Drops Amid Tough Markets in February
Date:3/3/2008

SAN FRANCISCO, March 3 /PRNewswire/ -- For the second month in a row the capital markets succumbed to fears of inflation and a weakening economy. On the last day of the month the Dow dropped over 300 points after oil prices pushed past $103 per barrel for the first time. Amid these fears, biotech was dragged down with the Burrill Biotech Select Index dropping 4% along with the NASDAQ, down 5% and the Dow, which closed down 3%.

"The biotech sector started 2008 on a positive note, outperforming the major indices in January," said G. Steven Burrill, CEO of Burrill & Company, a San Francisco based global leader in life sciences whose principal activities are in Private Equity, Venture Capital, Merchant Banking and Media. "However, in the wake of negative news from biotech's top performer Onyx Pharmaceuticals, the industry took a hit."

Onyx was the best-performing biotech stock of 2007, notching a one-year return of 440% ... but the company dropped 42.5% in February after reporting its cancer drug Nexavar failed a Phase III study in lung cancer patients. The study was testing the combination of Nexavar and the chemotherapy drugs carboplatin and paclitaxel in patients with non-small-cell lung cancer.

One of the few companies in the Index group to post a gain in February was Genentech (up 8%) on the strength that Avado, a Phase III study evaluating its cancer drug Avastin in combination with docetaxel chemotherapy, met its primary endpoint of prolonging progression-free survival in patients with advanced breast cancer. The Roche-sponsored Avado study investigated the addition of Avastin administered in two different dosages in combination with chemotherapy. Both doses of Avastin in combination with chemotherapy showed "statistically significant improvement" in the time patients lived without their disease advancing compared with chemotherapy and placebo.

The other was Illumina (up 13%). Its fourth-quarter revenue was up an impressive 86%. On the other side of the coin, shares of Vertex Pharmaceuticals were down 14% after reporting that a wider fourth-quarter loss will retard its 2008 outlook, which was below Wall Street expectations.

The Burrill Biotech Mid-Cap Index dropped 9% as investors migrated away from these companies. "Even though the pharmaceutical and biotech sectors are among the best for investors to be in during a recession, it is the blue-chip companies that they seek out. In difficult market conditions emerging biotech companies are viewed as more risky investments which is why most companies in the group lost value," noted Burrill.

Biotech IPOs remain on hold

The prevailing tough economic environment took its toll on biotech IPO "hopefuls" with Biolex, Light Sciences Oncology and Archemix cancelling their planned offerings because of the market conditions. Only one company braved the market -- Bioheart, a biotechnology company focused on using cells derived from a patient's body for treatment of heart damage. It priced its 1.1 million shares offering at $5.25 the midpoint of a revised range. The company had originally filed for an offering of 3.6 million shares at a range of $14-$16.

Market cap

The industry's market cap closed at $440 billion, unchanged for February. Genentech's market cap closed the month at $79B and second placed Amgen slipped 2% to $49B. Close on Amgen's heels is Gilead Sciences, which closed February at $44B.

Biotech Indices

Index 12/29/06 12/31/07 1/31/08 2/29/08 % %

change change

Month Year

Burrill Biotech

Select 303.96 331.52 331.31 318.05 -4.00% -4.06%

Burrill Large

Cap Biotech 424.56 437.71 438.87 434.25 -1.05% -0.79%

Burrill Mid-Cap

Biotech 171.55 201.89 179.33 161.7 -9.83% -19.91%

Burrill Small

Cap Biotech 143.6 137.6 148.3 150.15 1.25% 9.12%

Burrill Genomics 101.69 104.29 93.64 86.83 -7.27% -16.74%

Burrill AgBio 124.52 198.83 193.82 197.08 1.68% -0.88%

Burrill

Industrial 150.85 158.66 146.41 160.09 9.34% 0.90%

Burrill

Diagnostic 122.79 159.43 151.53 152.72 0.79% -4.21%

Burrill

Nutraceutical 629.56 593.04 556.24 546.94 -1.67% -7.77%

NASDAQ 2415.29 2652.28 2389.86 2271.48 -4.95% -14.36%

DJIA 12463.15 13264.82 12650.36 12266.39 -3.04% -7.53%

Russell 2000 787.66 766.03 713.3 686.18 -3.80% -10.42%

Amex Biotech 754.25 786.5 749.38 721.95 -3.66% -8.21%

Amex Pharma 345.06 338.52 316.45 305.15 -3.57% -9.86%


'/>"/>
SOURCE Burrill & Company
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genetic Engineering & Biotechnology News reports on advances in miRNA
2. Microchip Biotechnologies, Inc. Collaborating With Stanford University on Developing a Front End Microfluidic-Based Sample Preparation System for Pyrosequencing Platforms
3. Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents
4. Sigma-Aldrich Names Helge Bastian New VP of Global Marketing for Research Biotech
5. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
6. Biotech Pioneer William J. Rutter to Deliver Keynote at 2008 RAPS Horizons Conference
7. ZyGEM Appoints Leading Biotechnology Expert to Head Clinical Advisory Board
8. Marketing and Meeting Details (M2D) Offers Customized Convention Registration and Management Tool to Clients Inside and Outside of Pharma/Biotech
9. Biotech Crops Experience Remarkable Dozen Years of Double-Digit Growth
10. Raven biotechnologies to Provide Updates on Oncology Pipeline With Four AACR Presentations
11. Cord Blood America CEO Matthew Schissler Interviewed by BIONOVA, Greeces Leading Biotech Magazine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... March 23, 2017 NetworkNewsWire Editorial Coverage  ... Cancer ... significant strain on health care systems, in terms of costs ... so too does the development of innovative and efficient therapies ... Among the many types of cancer treatments, a growing number ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... announced the hire of Dr. Sigmund “Sig” Floyd as Vice President ? Global ... and joint development activities. , “Dr. Floyd’s career has spanned 30 years in ...
(Date:3/22/2017)... MONICA, Calif. , March 22, 2017 /PRNewswire/ ... are proud to announce their extended partnership and ... will be headlined by the 21 st ... BIOMEDevice Boston, taking place May 3-4, 2017. ... Advanced Medical Technology Association (ADVAMED) President and CEO, ...
(Date:3/22/2017)... ALBANY, New York , March 22, 2017 /PRNewswire/ ... market is largely fragmented, states a research report by ... Sanofi S.A., Pfizer Inc., Amgen Inc., and AbbVie Inc., ... market in 2015. The prominent players in this market ... to expand their product portfolio, which is likely to ...
Breaking Biology Technology:
(Date:3/2/2017)... Summary This report provides all ... and its partnering interests and activities since 2010. ... The Partnering Deals and Alliance since 2010 report provides ... of the world,s leading life sciences companies. ... ensure inclusion of the most up to date deal ...
(Date:2/28/2017)... 2017 News solutions for biometrics, bag drop ... ... 14 to 16 March, Materna will present its complete end-to-end ... travel is a real benefit for passengers. To accelerate the ... passenger touch point solutions to take passengers through the complete ...
(Date:2/22/2017)... -- With the biometrics market to exceed $10 ... that innovative and agile startups must incorporate into ... changing competitive landscape: multifactor authentication (MFA), point-of-sale (PoS), ... "Companies can no longer afford to cut corners ... Pavlakis , Industry Analyst at ABI Research. "Pairing ...
Breaking Biology News(10 mins):